phosphorylcholine has been researched along with Subarachnoid Hemorrhage in 5 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigates the role of sphingosylphosphorylcholine (SPC) in the mechanisms underlying cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 7.75 | Elevated concentrations of sphingosylphosphorylcholine in cerebrospinal fluid after subarachnoid hemorrhage: a possible role as a spasmogen. ( Akimura, T; Fujisawa, H; Kashiwagi, S; Kato, S; Kishi, H; Kobayashi, S; Kurokawa, T; Miwa, S; Mogami, K; Ogasawara, K; Ogawa, A; Sato, M; Shirao, S; Soma, M; Suzuki, M; Yumiya, Y, 2009) |
| " Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine -Rho-kinase-activated Ca(2+)-sensitization in vitro and in subarachnoid hemorrhage (SAH) models in vivo and has also been shown to inhibit the occurrence of cerebral vasospasm (CIV) after the onset of SAH in a prospective, nonrandomized study." | 5.19 | A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study. ( Nakagawara, J; Ogasawara, K; Shirao, S; Suzuki, M; Tominaga, T; Yoneda, H, 2014) |
| "This study investigates the role of sphingosylphosphorylcholine (SPC) in the mechanisms underlying cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 3.75 | Elevated concentrations of sphingosylphosphorylcholine in cerebrospinal fluid after subarachnoid hemorrhage: a possible role as a spasmogen. ( Akimura, T; Fujisawa, H; Kashiwagi, S; Kato, S; Kishi, H; Kobayashi, S; Kurokawa, T; Miwa, S; Mogami, K; Ogasawara, K; Ogawa, A; Sato, M; Shirao, S; Soma, M; Suzuki, M; Yumiya, Y, 2009) |
| "Flow diversion has revolutionised the treatment of intracranial aneurysms, and the Pipeline Embolization Device (PED) remains the only flow diverter (FD) approved in the USA." | 1.46 | First US experience with Pipeline Flex with Shield Technology using aspirin as antiplatelet monotherapy. ( Aguilar-Salinas, P; Brasiliense, LB; Hanel, RA; Sauvageau, E, 2017) |
| "Inflammation has an important function in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH); however, the mediators of this inflammatory response have not been clearly identified." | 1.37 | Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries. ( Hunter, I; Mathieson, FA; Nixon, GF; Wirrig, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanel, RA | 1 |
| Aguilar-Salinas, P | 1 |
| Brasiliense, LB | 1 |
| Sauvageau, E | 1 |
| Shirao, S | 3 |
| Fujisawa, H | 2 |
| Kudo, A | 1 |
| Kurokawa, T | 2 |
| Yoneda, H | 2 |
| Kunitsugu, I | 1 |
| Ogasawara, K | 3 |
| Soma, M | 2 |
| Kobayashi, S | 2 |
| Ogawa, A | 2 |
| Suzuki, M | 3 |
| Yumiya, Y | 1 |
| Kashiwagi, S | 1 |
| Sato, M | 1 |
| Kishi, H | 1 |
| Miwa, S | 1 |
| Mogami, K | 1 |
| Kato, S | 1 |
| Akimura, T | 1 |
| Wirrig, C | 1 |
| Hunter, I | 1 |
| Mathieson, FA | 1 |
| Nixon, GF | 1 |
| Nakagawara, J | 1 |
| Tominaga, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage[NCT00839449] | Phase 4 | 200 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study.
Topics: Aged; Arachidonic Acid; Cardiovascular Agents; Combined Modality Therapy; Eicosapentaenoic Acid; Fem | 2014 |
4 other studies available for phosphorylcholine and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
First US experience with Pipeline Flex with Shield Technology using aspirin as antiplatelet monotherapy.
Topics: Aneurysm, Ruptured; Angiography; Aspirin; Diffusion Magnetic Resonance Imaging; Embolization, Therap | 2017 |
Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway.
Topics: Animals; Basilar Artery; Benzopyrans; Cerebral Angiography; Cisterna Magna; Disease Models, Animal; | 2008 |
Elevated concentrations of sphingosylphosphorylcholine in cerebrospinal fluid after subarachnoid hemorrhage: a possible role as a spasmogen.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Calibration; Chromatography, High Pressure L | 2009 |
Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries.
Topics: Animals; Blood Platelets; Blotting, Western; Cells, Cultured; Cerebral Arteries; Chemokine CCL2; Ele | 2011 |